Use of a Systems Pharmacology Model Based Approach Toward Dose Optimization of Parathyroid Hormone Therapy in Hypoparathyroidism-Reference-Cited by-同舟云学术

Use of a Systems Pharmacology Model Based Approach Toward Dose Optimization of Parathyroid Hormone Therapy in Hypoparathyroidism

Published:2018-10-22 Issue:3 Volume:105 Page:710-718
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Khurana Manoj¹,Zadezensky Immo²,Lowy Naomi³,Roman Dragos³,Guettier Jean‐Marc⁴,Li Liang¹,Florian Jeffry³,Sahajwalla Chandrahas G.¹,Sinha Vikram⁵,Mehrotra Nitin⁵

Affiliation:

1. Office of Clinical Pharmacology Center for Drug Evaluation and Research US Food and Drug Administration (FDA) Silver Spring Maryland, USA

2. EMD Serono Washington DC USA

3. Office of New Drugs Center for Drug Evaluation and Research US Food and Drug Administration (FDA) Silver Spring Maryland, USA

4. Sanofi‐Aventis Deutschland GmbH Industriepark Hoechst Frankfurt Germany

5. Merck & Co North Wales Pennsylvania, USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1200

Reference23 articles.

1. Quantitative and systems pharmacology in the post‐genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. .

2. The Regulation of Renal Calcium Excretion: An Approach to Hypercalciuria

3. BLA125511 (Natpara®) FDA Label. .

4. BLA125511 FDA Medical Officer Review(page 48 of 169). .

5. PK in late phase trials: collecting PK data in late phase trials led to alleviating additional trials, drug approval, and better dosing;Wang Y.;Applied Clinical Trials,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applying quantitative and systems pharmacology to drug development and beyond: An introduction to clinical pharmacologists;Indian Journal of Pharmacology;2024-07

2. Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice;Journal of Pharmacokinetics and Pharmacodynamics;2024-06-21

3. A Phase I Randomized Trial of Once‐Daily Versus Twice‐Daily Recombinant Human Parathyroid Hormone (1‐84) for Hypoparathyroidism;JBMR Plus;2023-05-31

4. Model‐Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases;The Journal of Clinical Pharmacology;2022-12

5. Current practices for QSP model assessment: an IQ consortium survey;Journal of Pharmacokinetics and Pharmacodynamics;2022-08-11